
|Articles|September 27, 2014
- Head and Neck Cancers (Issue 2)
- Volume 2
- Issue 1
Sequencing Sorafenib and Lenvatinib in Thyroid Cancer
Author(s)Marcia S. Brose, MD, PhD, FASCO
Marcia S. Brose, MD, PhD, discusses using both sorafenib and lenvatinib as treatment options for thyroid cancer.
Advertisement
Articles in this issue
almost 12 years ago
Treatment Update: Unresectable Medullary Thyroid Canceralmost 12 years ago
The Side Effects of Lenvatinibalmost 12 years ago
Immune Checkpoint Inhibitors for Head and Neck Cancersalmost 12 years ago
Battling the Immunosuppressive Nature of Head and Neck CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
2
Exploring Psilocybin-Assisted Therapy for Cancer Patients' Trauma
3
FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer
4
Allostatic Load: The Role of Chronic Stress in Predicting Early-Onset Cancer Risk
5




























